BCR-ABL tyrosine kinase inhibitors are commonly employed for the treatment of chronic myeloid leukemia, yet their impact on human malignant melanoma remains uncertain. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.